Platelet concentrates: Balancing between efficacy and safety?

Presse Medicale

Volumn 45, Issue 7-8, 2016, Pages e289-e298

  Lozano, Miguel ^a   Cid, Joan ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; RIBOFLAVIN; SULFANILAMIDE; THROMBOCYTE CONCENTRATE;

APHERESIS; BACTERIAL INACTIVATION; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CELL SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG STORAGE; HEMOSTASIS; HUMAN; IN VITRO STUDY; INFECTION RISK; RISK REDUCTION; SEPSIS; SHORT SURVEY; THROMBOCYTE DISORDER; THROMBOCYTE TRANSFUSION; ULTRAVIOLET C RADIATION; ULTRAVIOLET RADIATION; ADVERSE EFFECTS; INFECTION; INFECTION CONTROL; PROCEDURES; TREATMENT OUTCOME;

HUMANS; INFECTION; INFECTION CONTROL; PLATELET TRANSFUSION; TREATMENT OUTCOME;

EID: 84986253837     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2016.06.020     Document Type: Short Survey

References (70)

1. [1] Sweeney, J.D., Lozano, M., Epidemiology of platelet transfusion. Sweeney, J.D., Lozano, M., (eds.) Platelet transfusion therapy, 2013, AABB Press, Bethesda, MD.
2. [2] Kaufman, R.M., Assmann, S.F., Triulzi, D.J., Strauss, R.G., Ness, P., Granger, S., et al. Transfusion-related adverse events in the Platelet Dose study. Transfusion 55 (2015), 144–153.
3. [3] Stolla, M., Refaai, M.A., Heal, J.M., Spinelli, S.L., Garraud, O., Phipps, R.P., et al. Platelet transfusion – the new immunology of an old therapy. Front Immunol, 6, 2015, 28.
4. [4] Novak, M., Preservation of stored blood with sulfanilamide. J Am Med Assoc 113 (1939), 2227–2229.
5. [5] Murphy, S., Kahn, R.A., Holme, S., Phillips, G.L., Sherwood, W., Davisson, W., et al. Improved storage of platelets for transfusion in a new container. Blood 60 (1982), 194–200.
6. [6] Reduction of the maximum platelet storage period to 5 days in an approved container. 1986, FDA memorandum: U. S. Food and Drug Administration, Rockville (MD).
7. [7] Lozano, M., Pathogen inactivation technologies for blood components. Blajchman, M., Cid, J., Lozano, M., (eds.) Blood component preparation: from benchtop to bedside, 2011, AABB Press, Bethesda, Maryland, 247–270.
8. [8] The Trial to Reduce Alloimmunization to Platlets Study Group, Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 337 (1997), 1861–1869.
9. [9] Benjamin, R., Eder, A.F., Bacterial contamination of platelet products. Sweeney, J., Lozano, M., (eds.) Platelet transfusion therapy, 2013, AABB Press, Bethesda, MD.
10. [10] Hillyer, C.D., Josephson, C.D., Blajchman, M.A., Vostal, J.G., Epstein, J.S., Goodman, J.L., Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematol Am Soc Hematol Educ Program, 2003, 575–589.
11. [11] Jacobs, M.R., Good, C.E., Lazarus, H.M., Yomtovian, R.A., Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clin Infect Dis 46 (2008), 1214–1220.
12. [12] Lafeuillade, B., Eb, F., Ounnoughene, N., Petermann, R., Daurat, G., Huyghe, G., et al. Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000 to 2008. Transfusion 55 (2015), 636–646.
13. [13] Benjamin, R.J., Stramer, S.L., Leiby, D.A., Dodd, R.Y., Fearon, M., Castro, E., Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission. Transfusion 52 (2012), 1913–1921 [quiz 2].
14. [14] Snyder, E.L., Stramer, S.L., Benjamin, R.J., The safety of the blood supply – time to raise the bar. N Engl J Med, 373, 2015, 882.
15. [15] Musso, D., Nhan, T., Robin, E., Roche, C., Bierlaire, D., Zisou, K., et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia. November 2013 to February 2014. Euro Surveill, 19, 2014, 1.
16. [16] Pietersz, R.N., Reesink, H.W., Panzer, S., Oknaian, S., Kuperman, S., Gabriel, C., et al. Bacterial contamination in platelet concentrates. Vox Sang 106 (2014), 256–283.
17. [17] Benjamin, R.J., McDonald, C.P., Workgroup ITTIDB, The international experience of bacterial screen testing of platelet components with an automated microbial detection system: a need for consensus testing and reporting guidelines. Transfus Med Rev 28 (2014), 61–71.
18. [18] Eder, A.F., Kennedy, J.M., Dy, B.A., Notari, E.P., Weiss, J.W., Fang, C.T., et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004–2006). Transfusion 47 (2007), 1134–1142.
19. [19] Murphy, W.G., Foley, M., Doherty, C., Tierney, G., Kinsella, A., Salami, A., et al. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 95 (2008), 13–19.
20. [20] Dumont, L.J., Kleinman, S., Murphy, J.R., Lippincott, R., Schuyler, R., Houghton, J., et al. Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion 50 (2010), 589–599.
21. [21] Pearce, S., Rowe, G.P., Field, S.P., Screening of platelets for bacterial contamination at the Welsh Blood Service. Transfus Med 21 (2011), 25–32.
22. [22] Sireis, W., Ruster, B., Daiss, C., Hourfar, M.K., Capalbo, G., Pfeiffer, H.U., et al. Extension of platelet shelf life from 4 to 5 days by implementation of a new screening strategy in Germany. Vox Sang 101 (2011), 191–199.
23. [23] Harm, S.K., Delaney, M., Charapata, M., Aubuchon, J.P., Triulzi, D.J., Yazer, M.H., Routine use of a rapid test to detect bacteria at the time of issue for nonleukoreduced, whole blood-derived platelets. Transfusion 53 (2013), 843–850.
24. [24] Dunbar, N.M., Kreuter, J.D., Marx-Wood, C.R., Dumont, L.J., Szczepiorkowski, Z.M., Routine bacterial screening of apheresis platelets on Day 4 using a rapid test: a 4-year single-center experience. Transfusion 53 (2013), 2307–2313.
25. [25] Tabor, E., The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39 (1999), 1160–1168.
26. [26] Lin, L., Cook, D.N., Wiesehahn, G.P., Alfonso, R., Behrman, B., Cimino, G.D., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37 (1997), 423–435.
27. [27] Lin, L., Hanson, C.V., Alter, H.J., Jauvin, V., Bernard, K.A., Murthy, K.K., et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 45 (2005), 580–590.
28. [28] Singh, Y., Sawyer, L.S., Pinkoski, L.S., Dupuis, K.W., Hsu, J.C., Lin, L., et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 46 (2006), 1168–1177.
29. [29] Castro, E., Girones, N., Bueno, J.L., Carrion, J., Lin, L., Fresno, M., The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy coat platelets. Transfusion 47 (2007), 434–441.
30. [30] Grass, J.A., Hei, D.J., Metchette, K., Cimino, G.D., Wiesehahn, G.P., Corash, L., et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 91 (1998), 2180–2188.
31. [31] Kwon, S.Y., Kim, I.S., Bae, J.E., Kang, J.W., Cho, Y.J., Cho, N.S., et al. Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sang 107 (2014), 254–260.
32. [32] Hauser, L., Roque-Afonso, A.M., Beyloune, A., Simonet, M., Deau, F.B., Burin des, R.N., et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood 123 (2014), 796–797.
33. [33] Goodrich, R.P., The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 78:Suppl. 2 (2000), 211–215.
34. [34] Perez-Pujol, S., Tonda, R., Lozano, M., Fuste, B., Lopez-Vilchez, I., Galan, A.M., et al. Effects of a new pathogen reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 45 (2005), 911–919.
35. [35] Ruane, P.H., Edrich, R., Gampp, D., Keil, S.D., Leonard, R.L., Goodrich, R.P., Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 44 (2004), 877–885.
36. [36] Cardo, L.J., Salata, J., Mendez, J., Reddy, H., Goodrich, R., Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 37 (2007), 131–137.
37. [37] Tonnetti, L., Thorp, A.M., Reddy, H.L., Keil, S.D., Goodrich, R.P., Leiby, D.A., Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion 52 (2012), 409–416.
38. [38] Keil, S.D., Kiser, P., Sullivan, J.J., Kong, A.S., Reddy, H.L., Avery, A., et al. Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion 53 (2013), 2278–2286.
39. [39] Fast, L.D., Dileone, G., Cardarelli, G., Li, J., Goodrich, R., Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice. Transfusion 46 (2006), 1553–1560.
40. [40] Marschner, S., Fast, L.D., Baldwin, W.M. III., Slichter, S.J., Goodrich, R.P., White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 50 (2010), 2489–2498.
41. [41] Seltsam, A., Muller, T.H., UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 38 (2011), 43–54.
42. [42] Terpstra, F.G., van't Wout, A.B., Schuitemaker, H., van Engelenburg, F.A., Dekkers, D.W., Verhaar, R., et al. Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates. Transfusion 48 (2008), 304–313.
43. [43] Mohr, H., Steil, L., Gravemann, U., Thiele, T., Hammer, E., Greinacher, A., et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 49 (2009), 2612–2624.
44. [44] Pohler, P., Muller, M., Winkler, C., Schaudien, D., Sewald, K., Muller, T.H., et al. Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products. Transfusion 55 (2015), 337–347.
45. [45] van Rhenen, D.J., Vermeij, J., Mayaudon, V., Hind, C., Lin, L., Corash, L., Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 79 (2000), 206–214.
46. [46] Picker, S.M., Speer, R., Gathof, B.S., Functional characteristics of buffy coat PLTs photochemically treated with amotosalen HCl for pathogen inactivation. Transfusion 44 (2004), 320–329.
47. [47] Lozano, M., Galan, A., Mazzara, R., Corash, L., Escolar, G., Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion 47 (2007), 666–671.
48. 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 44 (2004), 1732–1740.
49. [49] Slichter, S.J., Raife, T.J., Davis, K., Rheinschmidt, M., Buchholz, D.H., Corash, L., et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 46 (2006), 731–740.
50. [50] Janetzko, K., Hinz, K., Marschner, S., Goodrich, R., Klüter, H., Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS. Vox Sang 97 (2009), 234–239.
51. [51] van der Meer, P.F., Bontekoe, I.J., Daal, B.B., de Korte, D., Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?. Transfusion 55 (2015), 1900–1908.
52. [52] Galan, A.M., Lozano, M., Molina, P., Navalon, F., Marschner, S., Goodrich, R., et al. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion 51 (2011), 808–815.
53. [53] AuBuchon, J.P., Herschel, L., Roger, J., Taylor, H., Whitley, P., Li, J., et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 45 (2005), 1335–1341.
54. [54] Seghatchian, J., Tolksdorf, F., Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system – an update. Transfus Apher Sci 46 (2012), 221–229.
55. [55] Bashir, S., Cookson, P., Wiltshire, M., Hawkins, L., Sonoda, L., Thomas, S., et al. Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion 53 (2013), 990–1000.
56. [56] van Rhenen, D., Gulliksson, H., Cazenave, J.P., Pamphilon, D., Ljungman, P., Klüter, H., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 101 (2003), 2426–2433.
57. [57] McCullough, J., Vesole, D.H., Benjamin, R.J., Slichter, S.J., Pineda, A., Snyder, E., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 104 (2004), 1534–1541.
58. [58] Snyder, E., McCullough, J., Slichter, S.J., Strauss, R.G., Lopez-Plaza, I., Lin, J.S., et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 45 (2005), 1864–1875.
59. [59] Janetzko, K., Cazenave, J.P., Klüter, H., Kientz, D., Michel, M., Beris, P., et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 45 (2005), 1443–1452.
60. [60] Kerkhoffs, J.L., van Putten, W.L., Novotny, V.M., te Boekhorst, P.A., Schipperus, M.R., Zwaginga, J.J., et al. Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 150 (2010), 209–217.
61. [61] Slichter, S.J., Kaufman, R.M., Assmann, S.F., McCullough, J., Triulzi, D.J., Strauss, R.G., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 362 (2010), 600–613.
62. [62] Lozano, M., Knutson, F., Tardivel, R., Cid, J., Maymo, R.M., Lof, H., et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 153 (2011), 393–401.
63. [63] Vamvakas, E.C., Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 51 (2011), 1058–1071.
64. [64] Vamvakas, E.C., Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 102 (2012), 302–316.
65. [65] Cid, J., Escolar, G., Lozano, M., Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 103 (2012), 322–330.
66. [66] Osselaer, J.C., Doyen, C., Defoin, L., Debry, C., Goffaux, M., Messe, N., et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 49 (2009), 1412–1422.
67. [67] Cazenave, J.P., Isola, H., Kientz, D., Pathogen inactivation of platelets. Sweeney, J., Lozano, M., (eds.) Platelet transfusion therapy, 2013, AABB Press, Bethesda, MD.
68. [68] The Mirasol clinical evaluation study group, A randomized controlled clinical trial evaluating the performance and safety of platelets treated with Mirasol(R) pathogen reduction technology. Transfusion 50 (2010), 2362–2375.
69. [69] Rebulla, P., Vaglio, S., Aprili, G., Beccaria, F., Coluzzi, S., Girelli, G., et al. Clinical efficacy and safety of platelets in additive solution treated with two commercial pathogen reduction technologies. Transfusion, 55, 2015, 4A.
70. [70] Thiele, T., Pohler, P., Kohlmann, T., Sumnig, A., Aurich, K., Selleng, K., et al. Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction – a phase I clinical trial. Vox Sang 109 (2015), 44–51.